Royalty Pharma Acquires Royalty Interest in Cliramitug for Up to $425 Million
Royalty Pharma (RPRX) has agreed to acquire a portion of the royalty interest in cliramitug, a heart disease therapy developed by AstraZeneca and Neurimmune. The deal includes an upfront payment of $125 million with total potential payments reaching up to $425 million.
Tickers: $AZN